B Cell Receptor Signalling Regulation by Non-coding RNAs

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00071816" target="_blank" >RIV/65269705:_____/19:00071816 - isvavai.cz</a>

Výsledek na webu

<a href="https://eu-life.eu/sites/default/files/2019-11/Final%202019%20EU-Life%20Scientific%20Meeting_Abstract%20Book.pdf" target="_blank" >https://eu-life.eu/sites/default/files/2019-11/Final%202019%20EU-Life%20Scientific%20Meeting_Abstract%20Book.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

B Cell Receptor Signalling Regulation by Non-coding RNAs

Popis výsledku v původním jazyce

B Cell Receptor (BCR) signalling is fundamental for the maturation, survival, and proliferation of B cells, and B cell malignancies frequently harbour mutations in this pathway or complex non-genetic deregulation of BCR signalling. This is underscored by the remarkable clinical effect of inhibitors targeting BCR-associated kinases BTK and PI3K, especially in chronic lymphocytic leukaemia (CLL). The differences in BCR signalling propensity contribute to variable prognosis in CLL and other &quot;mature&quot; B cell malignancies, and it has been shown that non-coding RNAs such as miR-150, miR155, miR-34a or miR-17-92 play an important role in this process. The talk will focus on novel roles of microRNAs (miRNAs) in fine tuning the propensity of BCR signalling during microenvironmental interactions of B cells, and also the related changes during therapy with BCR inhibitors or classical DNA-damaging therapeutic drugs. This will include novel data on MYC-regulated and p53-regulated miRNAs acting as regulators of PI3K pathway. The data indicate that miRNA-induced changes in &quot;tonic&quot; and/or antigen-induced BCR signalling might be of key importance for the development and therapy resistance of B cell neoplasms.

Název v anglickém jazyce

B Cell Receptor Signalling Regulation by Non-coding RNAs

Popis výsledku anglicky

B Cell Receptor (BCR) signalling is fundamental for the maturation, survival, and proliferation of B cells, and B cell malignancies frequently harbour mutations in this pathway or complex non-genetic deregulation of BCR signalling. This is underscored by the remarkable clinical effect of inhibitors targeting BCR-associated kinases BTK and PI3K, especially in chronic lymphocytic leukaemia (CLL). The differences in BCR signalling propensity contribute to variable prognosis in CLL and other &quot;mature&quot; B cell malignancies, and it has been shown that non-coding RNAs such as miR-150, miR155, miR-34a or miR-17-92 play an important role in this process. The talk will focus on novel roles of microRNAs (miRNAs) in fine tuning the propensity of BCR signalling during microenvironmental interactions of B cells, and also the related changes during therapy with BCR inhibitors or classical DNA-damaging therapeutic drugs. This will include novel data on MYC-regulated and p53-regulated miRNAs acting as regulators of PI3K pathway. The data indicate that miRNA-induced changes in &quot;tonic&quot; and/or antigen-induced BCR signalling might be of key importance for the development and therapy resistance of B cell neoplasms.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů